LN 4311
Alternative Names: LN-4311Latest Information Update: 30 Apr 2026
At a glance
- Originator LigaChem Biosciences; Nectin Therapeutics
- Developer LigaChem Biosciences
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Apr 2026 LigaChem Biosciences plans to file an IND application in 2026 (LigaChem Biosciences pipeline, Mach 2026)
- 17 Oct 2025 Preclinical trials in Solid tumours in South Korea (Parenteral) prior to October 2025
- 17 Oct 2025 Pharmacodynamics data from preclinical studies in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)